Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
